Peptide receptor radionuclide therapy

Clinical Nuclear Medicine, 2022
Abstract Pheochromocytomatosis refers to pheochromocytoma tumorlets developed as a result of seeding of tumor cells around the surgical bed due to intraoperative tumor capsule rupture and tumor cell spillage. As pheochromocytomatosis is relatively rare, optimal management is not clear.
Martin S, Auerbach, Masha J, Livhits, Run, Yu +2 more
openaire +2 more sources

Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy

Current Topics in Medicinal Chemistry, 2013
The paper focuses on the β-emitting radionuclides which might be useful for peptide receptor radionuclide therapy, PRRT. For the effective design of the radiopharmaceutical, the choice of radionuclide will depend on the purpose for which the radioligand is being used and on the physicochemical properties of the radionuclide.
J L, Parus, R, Mikolajczak
openaire +2 more sources

Advances in Peptide Receptor Radionuclide Therapy

Seminars in Nuclear Medicine, 2016
Peptide receptor radionuclide therapy (PRRT) is a very effective treatment modality for advanced neuroendocrine tumors (NETs), representing a teaching model for truly targeted antitumor therapy. With the growing cumulative evidence of PRRT in various treatment settings, we are witnessing increased perception of this modality as a potent treatment ...
Sabet, Amir +2 more
openaire +3 more sources

3. good health
humans
neuroendocrine tumors

receptors, peptide
radiopharmaceuticals
radioisotopes

octreotide
organometallic compounds
prrt